Evelo Biosciences Inc (EVLO)

Evelo Biosciences Inc (EVLO) is a Biotechnology company in the Healthcare sector listed on the NASDAQ.

As of Oct 23, 2026: market cap $3,796; returns 1 day +0.0%.

Evelo Biosciences Inc. was a clinical-stage biotechnology company focused on discovering and developing oral medicines that act on immune cells in the small intestine with systemic effects. The company was developing EDP1815 as a treatment for psoriasis and atopic dermatitis, and EDP2939 in psoriasis. Other product candidates included EDP1867 for inflammatory diseases and EDP1908 for oncology.

Groups EVLO belongs to

• Biotechnology
• Biopharmaceutical
• Clinical Stage Biotech
• Healthcare
• Life Sciences
• Clinical Stage
• Autoimmune Diseases
• Chronic Inflammatory Diseases
• Immunotherapy
• Dermatology

EVLO financial model: income statement, cash flow and balance sheet